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Rituximab fixed retreatment versus
on-demand retreatment in refractory
rheumatoid arthritis: comparison of
two B cell depleting treatment
strategies
Rituximab, an anti-CD20 monoclonal antibody, has been
approved for treatment in patients with rheumatoid arthritis
(RA) who have failed treatment with tumour necrosis factor
(TNF) blocking agents.1 Previous studies have demonstrated its
safety, efficacy and prevention of radiographic progression;2 3
however few studies have yet addressed the timing of repeated
courses of rituximab. A study in 22 patients with RA showed
that treatment with repeated courses of rituximab over a 5-year
follow-up period was safe and well tolerated4 and additionally
an open-label extension study of 3 large randomised, double-
blind studies in patients with RA showed that clinical efficacy
was maintained with subsequent courses of rituximab, compar-
able to the first rituximab course, without increased additional
safety concerns.5 Interestingly, one study reported that
rituximab retreatment was more effective; however, this was
in patients whose disease activity had not completely returned
to baseline levels.6 Therefore, the preferred timing of repeated
treatment courses of rituximab is still a matter of debate and
thus far has not been prospectively investigated.
The present study compared the efficacy and safety of 2 B cell
depleting strategies in 48 patients with refractory RA failing
disease-modifying antirheumatic drugs (DMARD) combination
therapy and/or at least 1 TNF blocking agent. In a prospective,
two-centre, non-randomised, open-label pilot study, after initial
treatment with 261000 mg rituximab, one group (n = 28) in
one centre received fixed retreatment (FR) at 24 weeks with
161000 mg rituximab, while the other group (n = 20) in the
other centre received retreatment with the same dose at disease
relapse as on-demand retreatment (ODR). Clinical efficacy,
safety and immunological outcomes were evaluated every
12 weeks for a period of 1 year. Patients were allowed to
continue their daily or weekly dosages of DMARDs and
corticosteroids, however TNF blocking agents required an
8-week wash-out period. The study was approved by the local
ethics committees of both centres.
Patients in both treatment arms were comparable with
respect to baseline characteristics, as shown in table 1. After
1 year of follow-up, no significant differences were observed
Table 1 The cutoff value, sensitivity, specificity, negative and positive predictive values of procalcitonin,
TNFa, CRP and IL-6 for detecting bacterial infection in febrile patients with adult-onset Still’s disease
Cutoff value
Sensitivity
(%)
Specificity
(%)
NPV
(%)
PPV
(%) p Value
Procalcitonin (ng/ml)
1.4 100.0 100.0 100.0 100.0 ,0.001
0.5 100.0 76.9 100.0 66.7 ,0.001
TNFa (pg/ml)
14.0 83.3 76.9 90.9 62.5 0.002
CRP (mg/l)
101 73.1 83.3 58.1 90.5 0.004
IL-6 (pg/ml)
101 50.0 80.8 77.8 54.6 0.068
CRP, C-reactive protein; NPV, negative predictive value; PPV, positive predictive value; TNF-a, tumour necrosis factor alpha.
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between both treatment arms regarding change in 28-joint
Disease Activity Score (DAS28) results, change in Health
Assessment Questionnaire (HAQ) scores and radiographic
progression. Additionally, American College of Rheumatology
(ACR) and European League Against Rheumatism (EULAR)
response rates were comparable (table 1). Additionally, we
found that both treatments were equally safe: 86% of the
patients in the FR group compared to 95% in the ODR group
had reported an adverse event (p = 0.30). One patient died
8 weeks after initiation of rituximab treatment from respiratory
insufficiency due to progression of pre-existent lung fibrosis.
Infusion-related events were seen in 14% of patients in the FR
group and 30% in the ODR group (p = 0.19), of which all
reported symptoms were mild with a common toxicity criteria
(CTC) grade of 1 or 2.
We demonstrated that over a 1-year follow-up period
fixed retreatment and on-demand retreatment with rituxi-
mab resulted in comparable efficacy as measured by ACR
response, EULAR response, change in DAS28 results and
HAQ scores and radiographic progression. With respect to the
safety profile, both treatment strategies were comparable. The
present study warrants further randomised studies with longer
follow-up of repetitive retreatment courses with rituximab,
which are needed to evaluate different B cell depleting
strategies.
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Table 1 Study overview
Patient characteristics Fixed retreatment (n = 28) On-demand retreatment (n = 20) p Value
Baseline:
Age (years) 53.7 (32.5 to 81.5) 58.5 (25.8 to 83.8) 0.28
Female (%) 71 60 0.41
Disease duration (years) 13.2 (1.3 to 53.2) 13.4 (3.1 to 50) 0.99
Positive rheumatoid factor (%) 86 95 0.30
Positive ACPA status (%) 82 85 0.79
Previous DMARDs (no.) 4 (2 to 8) 5 (2 to 11) 0.05
Previous ant-TNF agents (no.) 1 (0 to 3) 2 (1 to 3) 0.05
Current DMARDs (no.) 1 (1 to 2) 1 (0 to 3) 0.85
DAS28 6.06 (3.01 to 7.67) 6.73 (5.17 to 8.51) 0.09
HAQ disability 1.63 (0.13 to 2.88) 1.50 (0.50 to 2.38) 0.66
Radiographic score* 56.5 (8 to 245) 52.5 (3 to 271) 0.57
At 1 year:
Change in DAS28{ 2.13 (0.03 to 4.10) 1.77 (0.20 to 5.78) 0.51
Change in HAQ disability{ 0.25 (20.50 to 1.88) 0.13 (20.63 to 1.50) 0.48
Radiographic progression* 5 (211 to 30) 4 (213 to 23) 0.33
ACR response
ACR20 (%) 64 53 0.47
ACR50 (%) 28 18 0.44
ACR70 (%) 4.0 5.9 0.78
EULAR response 0.481
No (%) 12 27
Moderate (%) 60 53
Good (%) 28 20
Adverse events:
Any adverse event 24 (86%) 19 (95%) 0.30
Serious adverse event 5 (18%) 3 (15%) 0.79
Infusion-related adverse event 4 (14%) 6 (30%) 0.19
Adverse event leading to withdrawal 4 (14%) 1 (5%) 0.30
Death 1 (4%) 0 (0%) 0.39
*As quantified by the Sharp-van der Heijde score; {positive scores indicate the points of improvement in DAS28-cores; {positive
scores indicate the points of improvement in HAQ-scores; 1p value was calculated by x2 test in contrast to non-parametric Mann–
Whitney U tests used for all other variables presented.
ACPA, anti-citrullinated protein/peptide antibodies; ACR, American College of Rheumatology; DAS28, 28-joint Disease Activity Score;
DMARD, disease-modifying antirheumatic drug; EULAR, European League Against Rheumatism; HAQ, Health Assessment
Questionnaire; TNF, tumour necrosis factor.
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Refractory severe connective tissue
disease thrombocytopenia: is
rituximab treatment effective and
safe?
Rituximab, a chimeric monoclonal antibody against B cell-
specific surface marker CD20, has shown encouraging results in
treating autoimmune diseases.1–4
In this study, six patients with refractory severe thrombocy-
topenia (platelets (PLT) 4 to 106109/litre) were treated with
rituximab (weekly infusion of 375 mg/m2 for 3–4 consecutive
weeks), including three cases of systemic lupus erythematosus,
one case each of primary Sjo¨gren syndrome, undifferentiated
connective tissue disease (CTD) and antiphospholipid syn-
drome (APS). Previous corticosteroids and immunosuppressive
agents in all patients were continued. Disease durations were
3 months to 13 years. Prior to rituximab therapy, all patients
had failed at least two courses of methylprednisolone pulse (1 g
per day for 3 consecutive days) in combination with intrave-
nous immunoglobulin (20 g per day for 3 to 5 consecutive
days) plus at least two immunosuppressants, including cyclo-
phosphamide, vincristine, mycophenolate mofetil and/or
ciclosporine A. Patients 2, 4 and 5 had also undergone
splenectomy without improvement. Five patients had suffered
from treatment-related adverse events, including femoral head
necrosis, secondary hypertension, diabetes and liver function
impairment, and patients 5 and 6 had histories of recurrent lung
infections (table 1).
After the first infusion of rituximab, platelet counts in-
creased within 1 week in patient 2 and 2 to 4 weeks in the other
five patients, and were all above 1006109/litre within 3 to
9 weeks. Along with the improvement of thrombocytopenia,
cutaneous haemorrhage and/or gastrointestinal bleeding dis-
appeared. In addition, autoimmune haemolytic anaemia in
patient 4 and proteinuria in patient 6 improved as well at week
2 and 7, respectively. Rituximab treatment had no significant
effect on serum levels of immunoglobulin, including IgG, IgA
and IgM.
B cell counts (cell/mm3) in patients 1, 3 and 5 at the time of
treatment were 480, 127 and 12, respectively. Complete B cell
depletion (defined as less than 5 cells/mm3) was obtained in all
three patients within 2 weeks after the first rituximab infusion.
The mechanism by which rituximab led to thrombocytopenia
remission may be through elimination of B lymphocytes
necessary for autoantibody production. However, patient 2
experienced an early response, raising the possibility that B cells
opsonised by anti-CD20 may contribute to Fc receptor
blockade.5–7
Table 1 Rituximab therapy in six cases of refractory severe connective tissue disease (CTD) thrombocytopenia
Patient Sex/age Disease
Disease
duration
(months) Clinical features Previous therapy
Adverse
events
Concurrent
therapy Infection
Duration of
follow-up
(months) Outcome
1 F, 21 SLE 3 Thrombocytopenia,
leukopenia,
hypocomplementaemia,
ANA(+), anti-dsDNA(+)
MP pulse, Pred,
CTX, VCR
None Pred, CsA None 13 CR
2 F, 54 UCTD 156 Thrombocytopenia,
arthritis, myalgia, ANA(+)
MP pulse, Pred,
CsA, VCR, IVIG,
splenectomy
FHN, HBP,
liver damage
Pred, MMF None 35 CR
3 F, 58 PSS 60 Parotid swelling,
thrombocytopenia, anti-
SSA(+), anti-SSB(+)
MP pulse, Pred,
MMF, IVIG
FHN Pred, CsA Herpes zoster,
lung infection
2 Death
4 M, 24 SLE 41 Evans syndrome,
hypocomplementaemia,
ANA(+), anti-dsDNA(+)
MP pulse, Pred,
CTX, VCR, IVIG,
splenectomy
FHN,HBP Pred, CsA Lung infection 6 CR
5 F, 41 APS 58 Thrombocytopenia, DVT,
PE, lupus anticoagulant
(+)
MP pulse, Pred,
CsA, CTX, VCR,
IVIG, splenectomy
Recurrent lung
infections, SID
Pred, CsA,
VCR
None 47 Thrombocytopenia
recurred after 13
months
6 F, 31 SLE 108 Fever, arthritis, serositis,
pancytopenia, class IV
LN, gastrointestinal
vasculitis,
hypocomplementaemia,
ANA(+),anti-dsDNA(+)
MP pulse, Pred,
CTX, CsA, IVIG
Recurrent lung
infections
Pred, CsA,
CTX
Pneumocystis
carinii
pneumonia
5 Death
APS, antiphospholipid syndrome; CR, complete remission; CsA, ciclosporin A; CTX, cyclophosphamide; DVT/PE, deep venous thrombosis/pulmonary embolism; FHN, femoral head
necrosis; HBP, hypertension; ILD, interstitial lung disease; IVIG, intravenous immunoglobulin; LN, lupus nephritis; MMF, mycophenolate mofetil; MP, methylprednisolone; MTX,
methotrexate; Pred, prednisone; PSS, primary Sjo¨gren syndrome; SID, steroid-induced diabetes; SLE, systemic lupus erythematosus; UCTD, undifferentiated connective tissue disease;
VCR, vincristine.
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